Crohn’s Disease – Unmet Need – Unmet Need – Moderate to Severe Crohn’s Disease (US/EU)
Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors, such as Johnson & Johnson Innovative Medicine’s Remicade and AbbVie’s Humira, have long been the mainstay of biological treatment for moderate to severe CD. However, these agents pose safety risks and have efficacy limitations, and non-TNF-targeted therapies have expanded treatment options. These include cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio), an interleukin (IL)-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s Stelara), a Janus kinase (JAK) inhibitor (AbbVie’s Rinvoq), and IL-23 inhibitors (AbbVie’s Skyrizi, Eli Lilly’s Omvoh, and Johnson & Johnson Innovative Medicine’s Tremfya). The increasing availability of biosimilar therapies has further complicated treatment decision-making in CD. Despite advances in therapy, significant unmet needs persist in CD, including treatment-refractory patients, complex manifestations such as fistulizing disease, and the need for improved administration and safety, continuing to provide opportunities for new drug development.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in moderate to severe CD?
- How do current therapies perform on treatment drivers and goals for moderate to severe CD?
- In addition to efficacy, which drug attributes most strongly influence physician prescribing behaviors, and which have a limited impact?
- What are the predominant areas of unmet need and hidden opportunity in the treatment of moderate to severe CD?
- What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new CD drug?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
KEY FEATURE
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European gastroenterologists fielded in December 2025
Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Takeda, Amgen, Celltrion Healthcare
Key drugs: Adalimumab, Infliximab, Entyvio, Rinvoq, Skyrizi, Stelara, Tremfya
